IntelGenx Technologies (OTCMKTS:IGXT) & Avenue Therapeutics (NASDAQ:ATXI) Critical Review

Profitability

This table compares Avenue Therapeutics and IntelGenx Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
IntelGenx Technologies	N/A	N/A	N/A

Earnings & Valuation

This table compares Avenue Therapeutics and IntelGenx Technologies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38 million	($0.95)	-0.75
IntelGenx Technologies	$1.04 million	28.05	-$9.93 million	($0.06)	-2.78

IntelGenx Technologies has higher revenue and earnings than Avenue Therapeutics. IntelGenx Technologies is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Avenue Therapeutics has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500. Comparatively, IntelGenx Technologies has a beta of 2.47, indicating that its stock price is 147% more volatile than the S&P 500.

Insider & Institutional Ownership

17.3% of Avenue Therapeutics shares are owned by institutional investors. 1.8% of Avenue Therapeutics shares are owned by company insiders. Comparatively, 42.0% of IntelGenx Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

IntelGenx Technologies beats Avenue Therapeutics on 7 of the 9 factors compared between the two stocks.

About Avenue Therapeutics

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

About IntelGenx Technologies

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.